Dividends Calendar Earnings Calendar
RUBY

RUBY | Rubius Therapeutics Inc

Healthcare sector
Rubius Therapeutics Inc
Category: Consumer goods
  • Industry: Biotechnology

Quick infos

  • Headquarters:   Massachusetts, United States

Trade prices

  • Volume:
  • Market Cap: 132.57M
  • Prev closed:
  • Open: 4.31
  • High: 4.56
  • Low: 4.27
  • 52 week low: 4.02
  • 52 week high: 38.71
  • Dividends:No Dividends

Next ER: May 10, 2022  Before Market Opens



Top Stories (RUBY)

    Company Profile

    Rubius Therapeutics developed our proprietary RED PLATFORM® to generate red blood cells and genetically engineer them into a new class of cellular medicines, called Red Cell Therapeutics™ (RCTs). Our RED PLATFORM harnesses both the unique properties of red blood cells and the creative potential of genetic engineering to deliver on the promise of cellular therapy and transform how diseases are treated.

    Earnings History

    Date EPS / Forecast Revenue / Forecast
    August 16, 2022
    May 10, 2022-0.58 / -0.5717- / -
    February 25, 2022-0.61 / -0.585- / -
    November 8, 2021-0.55 / -0.5633- / -
    August 9, 2021-0.56 / -0.4887- / -
    view more

    Historical Data

    DatePriceOpenHighLowVolChangeER
    May 10, 2022 1.47 1.70
    1.70
    1.36
    		 1.17M 10.53%
    May 9, 2022 1.33 1.41
    1.45
    1.30
    		 702.50K -6.99%
    May 6, 2022 1.43 1.49
    1.55
    1.38
    		 853.40K -2.72%
    May 5, 2022 1.47 1.63
    1.66
    1.46
    		 453.50K -11.45%
    May 4, 2022 1.66 1.71
    1.71
    1.52
    		 886.06K -4.05%
    May 3, 2022 1.73 1.71
    1.78
    1.67
    		 694.28K 0%
    May 2, 2022 1.73 1.65
    1.79
    1.59
    		 1.16M 4.22%
    Apr 29, 2022 1.66 1.70
    1.76
    1.59
    		 808.96K -4.6%
    Apr 28, 2022 1.74 1.86
    1.86
    1.56
    		 2.00M -3.33%
    Apr 27, 2022 1.80 1.71
    1.85
    1.65
    		 1.76M 2.86%
    view more
    NASDAQ - Nasdaq Stock Market

    More profiles and info about the company

    • Founded:2013
    • Employees:204

    News

    News for (RUBY)

    This company doesn't provide a dividend.

    Key Persons

    • CEO :  Pablo J Cagnoni

    Talk about Rubius Therapeutics Inc below in comments section below.

    Do you think you'll buy? Do you already have active trades now?

    EarningsAhead is not affiliated with and this is not an endorsement of the companies featured above.
    This profile is based on publicly available information and is intended to be informative in nature.

    Most of the datas are collected by our Data Entry and we aim to be as accurate as humanly possible.




    Other ER on May 10, 2022 (Same day)

    ea syy h su teo armk dar cron fnf wynn tdg epc 


    Jump to (Finance sites)

    Google   
             

    Research 


    Investor page

    ir.rubiustx.com

    If you are looking for News & events, Press Release, they are available on their Investors Relationssite.


    Consensus
    BUY 50
    HOLD 50
    SELL 0

    Their Official Profiles 

    TwitterLinkedInYoutube

    Support this project

    If you want to help pay for server cost or for improving this tool. You can send it via Paypal.
    More features coming soon :)

    Social Media 




    Recommended Books

    Technical Analysis For Dummies
    Buy on Amazon

    Technical analysis is a collection of techniques designed to help you make trading decisions in securities markets. Technical Analysis For Dummies helps you take a hard-headed look at what securities prices are actually doing rather than what economists or analysts say they should be doing, giving you the know-how to use that data to decide whether to buy or sell individual securities.

    A simple, straightforward guide to the fundamentals of technical analysis